PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 10, 1996New England Journal of Medicine1,109 citationsOpen Access

A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter

View Full Paper
SHScott M. HammerDKDavid KatzensteinMHMichael D. Hughes

Key Points

  • The aim is to compare the efficacy of nucleoside monotherapy versus combination therapy in HIV-infected adults with specific CD4 counts.
  • Compared treatments: zidovudine plus didanosine, zidovudine plus zalcitabine, and didanosine alone.
  • Population: HIV-infected adults with CD4 counts from 200 to 500 cells/mm³.
  • Analyzed survival rates and progression of HIV disease.
  • Combination therapy is superior to zidovudine alone in slowing HIV progression.
  • Increased survival rates observed in patients receiving combination therapy compared to monotherapy.

Abstract

Treatment with zidovudine plus didanosine, zidovudine plus zalcitabine, or didanosine alone slows the progression of HIV disease and is superior to treatment with zidovudine alone. Antiretroviral therapy can improve survival in patients with 200 to 500 CD4 cells per cubic millimeter.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hammer et al. (1996) studied this question.

synapsesocial.com/papers/69d6cf34f174babf6cab39bchttps://doi.org/10.1056/nejm199610103351501
Ask AI
Helpful
Bookmark
Share
View Full Paper